• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by SANUWAVE Health Inc.

    12/10/25 9:58:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care
    Get the next $SNWV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 11)


    SANUWAVE Health, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001

    (Title of Class of Securities)


    80303D305

    (CUSIP Number)


    JAMES E. BESSER
    c/o MANCHESTER MANAGEMENT COMPANY, LLC, 2 Calle Candina, #1701
    San Juan, PR, 00907
    (617) 399-1741

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    12/08/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    80303D305


    1 Name of reporting person

    MANCHESTER MANAGEMENT CO LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    947,979.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    947,979.00
    11Aggregate amount beneficially owned by each reporting person

    947,979.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.1 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    CUSIP No.
    80303D305


    1 Name of reporting person

    MANCHESTER EXPLORER, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    863,980.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    863,980.00
    11Aggregate amount beneficially owned by each reporting person

    863,980.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    80303D305


    1 Name of reporting person

    JAMES E. BESSER
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,000.00
    8Shared Voting Power

    947,979.00
    9Sole Dispositive Power

    2,000.00
    10Shared Dispositive Power

    947,979.00
    11Aggregate amount beneficially owned by each reporting person

    947,979.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    80303D305


    1 Name of reporting person

    MORGAN C. FRANK
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    52,653.00
    8Shared Voting Power

    863,980.00
    9Sole Dispositive Power

    863,980.00
    10Shared Dispositive Power

    872,605.00
    11Aggregate amount beneficially owned by each reporting person

    916,633.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    10.7 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    80303D305


    1 Name of reporting person

    MANCHESTER MANAGEMENT PR, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    PUERTO RICO
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    947,979.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    947,979.00
    11Aggregate amount beneficially owned by each reporting person

    947,979.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.1 %
    14Type of Reporting Person (See Instructions)

    IA



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001
    (b)Name of Issuer:

    SANUWAVE Health, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    9600 W. 76th Street, Suite 118, Eden Prairie, MINNESOTA , 55344.
    Item 2.Identity and Background
    (a)
    This Schedule 13D amendment is being filed jointly by Manchester Management PR, LLC, a Puerto Rican limited liability company ("Manchester"), Manchester Explorer, L.P., a Delaware limited partnership (the "Explorer"), Manchester Management Company, LLC, a Delaware limited liability company (the "GP"), James E. Besser ("Besser"), a United States citizen and Morgan C. Frank ("Frank"), a United States citizen (collectively, the "Reporting Persons").
    (b)
    The principal business address for each of the Reporting Persons is 2 Calle Candina, #1701, San Juan, Puerto Rico, 00907.
    (c)
    Besser is the managing member of Manchester and the GP and Frank serves as a portfolio manager and as a consultant for Explorer. The principal business of Manchester is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Manchester is the investment manager to Explorer and the GP is the general partner of Explorer. The principal business of Explorer is purchasing, holding and selling securities for investment purposes.
    (d)
    During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.
    (e)
    During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.
    (f)
    This Schedule 13D amendment is being filed jointly by Manchester Management PR, LLC, a Puerto Rican limited liability company ("Manchester"), Manchester Explorer, L.P., a Delaware limited partnership (the "Explorer"), Manchester Management Company, LLC, a Delaware limited liability company (the "GP"), James E. Besser ("Besser"), a United States citizen and Morgan C. Frank ("Frank"), a United States citizen (collectively, the "Reporting Persons").
    Item 3.Source and Amount of Funds or Other Consideration
     
    The funds for the purchase of the Shares for each of Besser and Frank came from their personal funds and from the working capital of Explorer and other private funds managed by the GP, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.
    Item 4.Purpose of Transaction
     
    There are no material changes to Item 4 of the Schedule 13D amendment, submitted on October 22, 2024. The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own. The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.
    Item 5.Interest in Securities of the Issuer
    (a)
    1As of the date hereof: (i) Besser may be deemed to be the beneficial owner of 947,979 Shares, constituting 11.1% of the Shares*; (ii) Frank may be deemed to be the beneficial owner of 916,633 Shares, constituting 10.7% of the Shares*; (iii) Manchester and the GP may be deemed to be the beneficial owner of 947,979 Shares, constituting 11.1% of the Shares*; (iv) Explorer may be deemed to be the beneficial owner of 863,980 Shares, constituting 10.1% of the Shares*
    (b)
    Besser: Besser has the sole power to vote or direct the vote of 2,000 Shares; has the shared power to vote or direct the vote of 947,979 Shares; has the sole power to dispose or direct the disposition of 2,000 Shares; and has the shared power to dispose or direct the disposition of 947,979 Shares. Frank: Frank has the sole power to vote or direct the vote of 52,653 Shares; has the shared power to vote or direct the vote of 863,980 Shares; has the sole power to dispose or direct the disposition of 52,653 Shares; and has the shared power to dispose or direct the disposition of 863,980 Shares. Manchester and GP: Manchester and the GP have the sole power to vote or direct the vote of 0 Shares; have the shared power to vote or direct the vote of 947,979 Shares; have the sole power to dispose or direct the disposition of 0 Shares; and have the shared power to dispose or direct the disposition of 947,979 Shares. Explorer: Explorer has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 863,980 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 863,980 Shares.
    (c)
    Excluding the transactions described in Item 6 and disclosed on Exhibit B, the Reporting Persons have not transacted in shares of the Issuer within the previous 60 days.
    (d)
    Except as otherwise disclosed herein, all of the securities reported in this Schedule 13D Amendment No. 11 are directly owned by advisory clients of Manchester Management PR, LLC. None of those advisory clients, other than Explorer, may be deemed to beneficially own more than 5% of the Shares.
    (e)
    Not applicable. *The outstanding Shares figure reflects 8,576,164 shares issued and outstanding, as reported on the Issuer's 10-Q filed on November 6, 2025.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described herein and/or in a previous Schedule 13D filed by the Reporting Persons in respect of the Issuer.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    MANCHESTER MANAGEMENT CO LLC
     
    Signature:/s/ James E. Besser
    Name/Title:James E. Besser, Managing Member
    Date:12/10/2025
     
    MANCHESTER EXPLORER, L.P.
     
    Signature:/s/ James E. Besser
    Name/Title:James E. Besser, Managing Member of the General Partner
    Date:12/10/2025
     
    JAMES E. BESSER
     
    Signature:s/ James E. Besser
    Name/Title:James E. Besser
    Date:12/10/2025
     
    MORGAN C. FRANK
     
    Signature:s/ Morgan C. Frank
    Name/Title:Morgan C. Frank
    Date:12/10/2025
     
    MANCHESTER MANAGEMENT PR, LLC
     
    Signature:/s/ James E. Besser
    Name/Title:James E. Besser, Managing Member
    Date:12/10/2025
    Get the next $SNWV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNWV

    DatePrice TargetRatingAnalyst
    9/3/2025$55.00Outperform
    Northland Capital
    7/29/2025$49.00Buy
    Roth Capital
    More analyst ratings

    $SNWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026. Those wishing to meet with company management during the conference should reach out to [email protected] to schedule a time. About SanuwaveSanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, muscul

    12/10/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

    Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers®, home health agencies, and skilled nursing facilities. Sanuwave plans to roll out the UltraMIST system to Healogics iSupply members at initi

    12/8/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Announces Q3 FY2025 Financial Results

    Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo

    11/7/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on SANUWAVE Health with a new price target

    Northland Capital initiated coverage of SANUWAVE Health with a rating of Outperform and set a new price target of $55.00

    9/3/25 9:10:05 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on SANUWAVE Health with a new price target

    Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00

    7/29/25 7:40:14 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by SANUWAVE Health Inc.

    SCHEDULE 13D/A - SANUWAVE Health, Inc. (0001417663) (Subject)

    12/10/25 9:58:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

    11/7/25 6:10:06 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by SANUWAVE Health Inc.

    10-Q - SANUWAVE Health, Inc. (0001417663) (Filer)

    11/6/25 4:52:01 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director by Deputization Manchester Management Co Llc sold $4,450,061 worth of shares (144,810 units at $30.73) (SEC Form 4)

    4/A - SANUWAVE Health, Inc. (0001417663) (Issuer)

    12/11/25 3:08:20 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc sold $4,450,061 worth of shares (144,810 units at $30.73) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    12/10/25 9:21:02 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Large owner Opaleye Management Inc. bought $38,361 worth of shares (1,267 units at $30.28) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    10/9/25 7:09:55 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $38,361 worth of shares (1,267 units at $30.28) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    10/9/25 7:09:55 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Large owner Opaleye Management Inc. bought $203,875 worth of shares (7,998 units at $25.49) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    4/30/25 7:06:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Financials

    Live finance-specific insights

    View All

    Sanuwave Announces Q3 FY2025 Financial Results

    Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo

    11/7/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

    EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515aMaterials for the conference call will be include

    11/3/25 4:35:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)

    Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 millio

    10/6/25 4:01:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Leadership Updates

    Live Leadership Updates

    View All

    Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat

    6/3/25 7:30:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health Appoints Greg Bazar to Board of Directors

    EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,

    5/28/25 4:05:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care